Franck Rahaghi, MD
Pulmonary Disease · Weston, FLNPI 1730137597
Payments from drug & device makers
Across 1,859 payments — averaging $831.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$447K
- Mallinckrodt Hospital Products Inc.$238K
- Actelion Pharmaceuticals US, Inc.$150K
- Bayer$115K
- Takeda Pharmaceuticals U.S.A., Inc.$105K
- Actelion Pharmaceuticals, Ltd$102K
- plus $387K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 550 | $446,922 |
| Mallinckrodt Hospital Products Inc. | 178 | $238,090 |
| Actelion Pharmaceuticals US, Inc. | 282 | $150,250 |
| Bayer | 165 | $115,451 |
| Takeda Pharmaceuticals U.S.A., Inc. | 101 | $105,260 |
| Actelion Pharmaceuticals, Ltd | 20 | $101,943 |
| Mallinckrodt Enterprises LLC | 69 | $91,253 |
| Boehringer Ingelheim | 114 | $87,576 |
| Janssen Research & Development, LLC | 12 | $57,876 |
| Grifols USA, LLC | 72 | $41,584 |
| Genentech USA, Inc. | 57 | $34,765 |
| Shire North American Group Inc | 43 | $21,234 |
| Merck | 16 | $17,085 |
| ANI Pharmaceuticals, Inc. | 21 | $14,293 |
| Cumberland Pharmaceuticals, Inc. | 8 | $10,088 |
| Genentech, Inc. | 2 | $3,025 |
| CSL Behring | 4 | $2,350 |
| AstraZeneca | 42 | $1,682 |
| GSK | 48 | $1,351 |
| Grifols Shared Services North America, Inc. | 4 | $972 |
| Sandoz | 11 | $485 |
| Novartis | 12 | $347 |
| Insmed, Inc. | 3 | $260 |
| Gilead | 7 | $199 |
| Inari Medical, Inc. | 1 | $193 |
| Intuitive Surgical | 2 | $157 |
| Regeneron Healthcare Solutions, Inc. | 2 | $147 |
| Circassia Inc. | 6 | $101 |
| Pfizer | 2 | $63 |
| Sanofi | 1 | $24 |
| Covidien LP | 1 | $17 |
| Pulmonx Corporation | 1 | $17 |
| Boston Scientific | 1 | $13 |
| Inogen, Inc. | 1 | $11 |
How this compares
$1,545,084 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Weston
- Anas HadehWeston$844K
- Jinesh MehtaWeston$645K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.